Metagenics PainX. For Neuromuscular Function and Pain Relief.
$64.95 incl. GST
Metagenics PainX
For Neuromuscular Function and Pain Relief
Size: 120g powder (12 days) Raspberry Flavour
Metagenics PainX Summary:
- Reduces and relieves nerve pain and persistent muscular pain, cramps, and spasm.
- For neuromuscular pain, such as shoulder and back pain, head and neck pain, sciatic pain, and fibromyalgia pain.
- PEA is analgesic and anti-inflammatory, exerts endocannabinoid activity and reduces pain amplification and muscle pain.
- Contains highly bioavailable PEA and exclusive Meta Mag Magnesium.
Metagenics PainX is Free from animal products, dairy protein, lactose, eggs, gluten, wheat, nuts, yeast and soy protein.
Metagenics PainX AUST L 376652
Benefits: Metagenics PainX
Key Clinical Applications:
- Low back pain
- Muscle cramps and spasms
- Chronic jaw pain
- Migraine/headache
- Fibromyalgia
Relieves neuromuscular pain: Magnesium exerts muscle-relaxing actions (and prevents muscle spasms) via multiple mechanisms and is a natural glutamate antagonist.1 Glutamate is involved in central sensitisation and pain amplification.2 Magnesium regulates neuromuscular transmission by blocking the entry of calcium ions in synaptic nerve terminals,3 as well as inhibiting presynaptic acetylcholine release, which propagates impulses between motor nerves and muscles.4
Higher magnesium intake has found to be protective against chronic pain.5 However, one third of Australian adults fail to meet their requirements for adequate magnesium intake.6 PainX contains 420 mg/d to support adults to meet the recommended intake of 310 to 320 mg/d in women and 400 to 420 mg/d in men.7
Figure 1: Magnesium and PEA Address Multiple Drivers of Pain Amplification.
Palmitoylethanolamide (PEA) promotes endogenous cannabinoid system (ECS) activity through its ability to augment the activity of cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).8
These receptors are expressed in nerve tissue and immune cells and are involved in modulating the inflammatory response by suppressing immune cell activation, which can reduce pain perception.9 PEA proves to be effective and safe in nerve compression syndromes. In one pivotal, double blind, placebo-controlled trial in 636 sciatic pain patients, subjective pain scores were reduced from 6.5/10 to 3.6/10 in the 300 mg/d group, while in the 600 mg/d group scores were reduced from 7.1/10 to 2.1/10 compared to placebo, which decreased from 6.6/10 to 4.6 (Figure 2).10
Figure 2: Outcomes of 600 mg/d of PEA on Sciatic Pain.
Meta Mag and Levagen+ are both exclusive types of magnesium and PEA, respectively, that show enhanced bioavailability.11 Meta Mag is different to magnesium salts and other magnesium chelates because it is covalently bound to two glycine molecules.12 Levagen+ is a highly bioavailable PEA using LipiSperse technology for enhanced absorption.13 The Levagen+ absorption studies show that Levagen+ is 1.7 times better absorbed and that it stays in the plasma for a longer period of time compared to a standard PEA (Levagen) (Figure 3). Clinically, 600 mg/d of Levagen+ PEA is likely to equate to consuming 1,000 mg/d of a standard micronised PEA (Levagen). A Practitioner can expect Levagen+ to produce greater efficacy and to last longer in the body.14
Figure 3: Levagen+ PEA vs Standard PEA
Levagen+ is owned by Gencor Pacific Limited.
Meta Mag is a registered trademark of Balchem Corp
